biologics
31.10.2011
Swiss drugs industry supplier Lonza is set to grow underlying sales and operating profit this year despite the strong Swiss franc as it benefits from robust demand from pharmaceutical groups, particularly at a plant in China.
more10.03.2010
Facet Biotech has agreed to be acquired by Abbott Laboratories for $27 a share, topping a hostile offer of $17.50 a share made last year by Biogen Idec. Shares of Facet rose 67% after the announcement.
Abbott and Facet said on Tuesday that the cash deal will have a net cost of about $450 million, including a purchase price of about $722 million less Facet's cash and securities of around $272 million.
more08.03.2010
Wacker Chemie has opened a new production facility for pharmaceutical proteins - also known as biologics - in Jena, Germany. The new plant is part of the Munich-based chemical company's investment program to enlarge its biotech operations. The company said the expansion enables it to accommodate its customers' rapidly growing demand for biotechnologically manufactured pharmaceuticals. Biologics are used to treat, among other things, cancer, multiple sclerosis and hepatitis.
more